Harmony Biosciences
-
Three Montgomery County Companies Make Business Insider’s 2026 High-Growth List
Three Montgomery County companies have earned national recognition for something increasingly rare in today’s volatile markets: consistent, profitable growth. Globus…
-
Plymouth Meeting Pharmaceutical Company Eyes $1B Milestone
Harmony Biosciences says its flagship narcolepsy drug is on track to hit a major milestone, writes John George for The…
-
Flagship Drug Sales Boost Plymouth Meeting-Based Harmony Biosciences Stock
Plymouth Meeting-based Harmony Biosciences saw its stock rise by almost 13 percent Thursday after reporting positive sales growth for Wakix,…
-
Plymouth Meeting’s Harmony Biosciences Drug Trial Misses Mark, Shares Drop
Plymouth Meeting’s Harmony Biosciences saw its stock tumble more than 16% this week, writes John George for the Philadelphia Business…
-
Plymouth Meeting’s Harmony Biosciences Pivots After FDA Rejects Wakix for Sleep Disorder
Plymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug, Wakix,…
-
Plymouth Meeting’s Harmony Biosciences Eyes $3B in Sales with New Treatments on the Way
Since launching in 2017, Plymouth Meeting’s Harmony Biosciences has grown from a small drug developer into a billion-dollar company, writes…
-
Harmony Biosciences in Plymouth Meeting OK’d for Sleep Disorder Drug Use
Plymouth Meeting-based Harmony Biosciences received a green light from the Food and Drug Administration to widen the use of Wakix,…
-
Plymouth Meeting-Based Harmony Biosciences Seeks FDA Nod for Pediatric Use of Narcolepsy Drug Wakix
The Food and Drug Administration (FDA) is set to decide by Thursday on Plymouth Meeting-based Harmony Biosciences‘ application to expand…
-
Plymouth Meeting-based Harmony Biosciences Acquires Epygenix Therapeutics, Adds Potential Epilepsy Treatment to Pipeline
Plymouth Meeting-based Harmony Biosciences acquired Epygenix Therapeutics of Paramus, New Jersey, last month, which added a potential treatment for epilepsy…
-
Plymouth Meeting-based Harmony Biosciences Enters Exclusive Licensing Deal for Potential New Narcolepsy Therapy
Harmony Biosciences, a Plymouth Meeting-based pharmaceutical company, has entered into an exclusive licensing deal for the rights to develop and…
-
FDA Asked to Withdraw Approval of Harmony Biosciences’ Narcolepsy Drug; Review Pending
Scorpion Capital filed a citizens petition with the U.S. Food and Drug Administration asking to have the federal agency reverse…
-
Plymouth Meeting’s Harmony Biosciences Holdings Acquires Zynerba Pharmaceuticals
Harmony Biosciences Holdings in Plymouth Meeting has agreed to buy Zynerba Pharmaceuticals for up to $200 million, writes John George…
-
Plymouth Meeting Executive Campus for Sale: One Valuation Estimates a Nine-Figure Windfall
The five buildings that comprise the Plymouth Meeting Executive Campus are on the market, and a ballpark valuation sees more…
-
These Two Montco-Based Companies Awarded for ‘Driving the Region’s Innovation Scene Forward’
Two Montgomery County companies are among the winners of the inaugural Fire Awards presented by the Philadelphia Business Journal, writes…
-
Plymouth Meeting Biotech Firm Stock Soars Following IPO
Shares of Plymouth Meeting-based Harmony Biosciences Holdings soared as much as 70 percent over the public offering price on the…
-
Harmony Biosciences Looking to Raise $100 Million in IPO to Study Key Ingredient in Wakix
Plymouth Meeting-based Harmony Biosciences, which markets the drug Wakix for patients with narcolepsy, is planning to raise $100 million with…
-
Plymouth Meeting company completes $270M fundraising round
They’re raising a lot more than your average crops on this ‘pharm.’ A new drug designed to combat narcolepsy at…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
